2-oxoethyl dodecanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-oxoethyl dodecanoate
• 英文别名: 2-Oxoethyl dodecanoate
• 化学式: C₁₄H₂₆O₃
• 分子量: 242.359
• InChiKey: YGAAOLGOQPQJQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  17
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-oxoethyl dodecanoate 、 盐酸万古霉素 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 、 甲醇 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  WO2020106791A5

  摘要：

  公开号：

  WO2020106791A5
• 作为产物：
  描述：

  2-羟基乙基月桂酸酯 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-oxoethyl dodecanoate
  参考文献：
  名称：

  Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections

  摘要：

  耐甲氧西林慢性肺病 金黄色葡萄球菌 (囊性纤维化（CF）中的慢性肺部耐甲氧西林金黄色葡萄球菌（MRSA）疾病在接受标准抗生素治疗后复发的可能性很高，这是一个与预期寿命缩短相关的未满足需求领域。我们开发了一种专为肺部给药而定制的脂聚糖肽疗法，它不仅对浮游的 MRSA 具有强效活性，而且还对生物膜和细胞内的 MRSA 受保护菌落具有强效活性，后者与临床抗生素失效有关。

  DOI：

  10.1128/aac.00316-21

文献信息

• Lipo-glycopeptide cleavable derivatives and uses thereof
  申请人：Insmed Incorporated

  公开号：US11071769B2

  公开（公告）日：2021-07-27

  The present invention provides certain lipo-glycopeptide cleavable derivatives and methods for using the same for the treatment of bacterial infections, for example, pulmonary bacterial infections. The LGPC derivatives include a cleavable moiety that in certain embodiments, is designed to allow for cellular uptake and/or a more rapid clearance of the glycopeptide metabolite (i.e., the cleaved glycopeptide) from the site of administration (e.g., the lung) as compared to the uncleaved LGPC.

  本发明提供了某些脂质糖肽可裂解衍生物以及使用其治疗细菌感染（例如肺部细菌感染）的方法。LGPC衍生物包括一个可裂解分子，在某些实施方案中，与未裂解的LGPC相比，可使细胞摄取和/或更快地从给药部位（如肺部）清除糖肽代谢物（即已裂解的糖肽）。
• LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF
  申请人：Insmed Incorporated

  公开号：EP3630154A1

  公开（公告）日：2020-04-08
• TRPV1 Modulator Compounds
  申请人：ANTALGENICS, S.L.

  公开号：US20200199063A1

  公开（公告）日：2020-06-25

  The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R 1 , R 2 , R 6 and R 6′ are independently selected from H, (C 1 -C 8 )alkyl, unsaturated (C 2 -C 8 )hydrocarbon, and (C 3 -C 6 )cycloalkyl, being these groups optionally substituted; R 3 is hydrogen or halogen; R 4 is selected from H, (C 1 -C 8 )alkyl, unsaturated (C 2 -C 8 )hydrocarbon, (C 3 -C 6 )cycloalkyl, (C 6 -C 12 )aryl, and (C 5 -C 12 )heteroaryl, being these groups optionally substituted; and R 5 is selected from (C 3 -C 28 )alkyl, unsaturated (C 3 -C 28 )hydrocarbon, (C 6 -C 12 )aryl, and (C 5 -C 12 )heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications.
• [EN] LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS CLIVABLES DE LIPO-GLYCOPEPTIDES ET LEURS UTILISATIONS
  申请人：INSMED INC

  公开号：WO2018217808A1

  公开（公告）日：2018-11-29

  The present invention provides certain lipo-glycopeptide cleavable derivatives and methods for using the same for the treatment of bacterial infections, for example, pulmonary bacterial infections. The LGPC derivatives include a cleavable moiety that in certain embodiments, is designed to allow for cellular uptake and/or a more rapid clearance of the glycopeptide metabolite (i.e., the cleaved glycopeptide) from the site of administration (e.g., the lung) as compared to the uncleaved LGPC.
• WO2020106791A5
  申请人：——

  公开号：WO2020106791A5

  公开（公告）日：2022-11-21